Vietnam market overview 2q2014 USD

VIETNAM MARKET OVERVIEW
2Q - 2014


Agenda slide

• Market Overview
• Survey Market Top Lines
• Leading Corporations
• Leading Products
• New Products

2


MAT

Therapy Classes Level 1 Performance

2Q 14

Survey Market: US$ 2,432 mill (+5%)
M - MUSC ULOSKELETAL SYSTEM
(G:10% EI: 105)
5.5%

K - HOSPITAL
SOLUTIONS (G:5% EI:
101)
4.5%

V - VARIOUS (G:6% G - G.U.SYSTEM & SEX
HORMONES (G:4% EI:
EI: 102)
100)
4.1%
3.8%
D DERMATOLOGIC ALS
(G:13% EI: 108)
3.6%

R - RESPIRATORY
SYSTEM (G:14% EI:
109)
6.0%

B - BLOOD +
B.FORMING ORGANS
(G:1% EI: 97)
3.4%
S - SENSORY ORGANS
(G:23% EI: 117)
2.1%

N - NERVOUS SYSTEM
(G:6% EI: 101)
6.6%
LANTINEOPLAST+IMMU
NOMODUL (G:14% EI:
109)
6.8%

C - C ARDIOVASC ULAR
SYSTEM (G:5% EI:
101)
11.2%
A - ALIMENTARY T.&
METABOLISM (G:3%
EI: 99)
19.5%

3

J - SYSTEMIC ANTIINFEC TIVES (G:-3%
EI: 92)
20.9%

H - SYSTEMIC
HORMONES (G:5% EI:
101)
1.4%
T - DIAGNOSTIC
AGENTS (G:9% EI:
104)
0.6%

P - PARASITOLOGY
(G:2% EI: 97)
0.2%

MAT

Regions Performance

2Q 14

Survey Market: US$ 2,432 mill (+5%)

CAN THO (G:9%; E:104)
3.9%
HANOI (G:9%; E:104)
18.9%

DA NANG (G:14%;
E:109)
2.9%

HCMC (G:1%; E:96)
31.9%

ALL OTHER (G:4%;
E:100)
39.8%

4

HAI PHONG (G:14%;
E:109)
2.6%

MAT

Regions Performance

2Q 14

Pharmacy

Hospital

Survey Market: US$ 886 mill (+8%)

Survey Market: US$ 1,546 mill (+3%)

CAN THO
(G:4%;
E:101)
2.5%

CAN THO
(G:12%;
E:104)
6.4%
HANOI
(G:5%; E:98)
19.3%

HCMC
(G:4%; E:96)

30.3%

5

ALL OTHER
(G:10%;
E:102)
34.4%

DA NANG
(G:21%;
E:112)
5.3%
HAI PHONG
(G:12%;
E:104)
4.3%

HCMC (G:1%; E:97)
32.8%

HANOI
(G:11%;
E:108)
18.7%

ALL OTHER
(G:2%; E:99)
42.9%

HAI PHONG
(G:16%;
E:113)
1.6%
DA NANG
(G:3%;
E:100)
1.5%


6

2Q
14

1Q
14

2.68

2.54

2.62

2.72

2.59
2Q
13

4Q
13

2.61

1Q
13

2.76

2.61

4Q
12

3Q
13

2.56

3Q
12

2.44

2.37

1Q
12
2Q

12

2.37

4Q
11

2.21

2Q
11

2.33

2.22

1Q
11

3Q
11

2.22

2.41

4Q
10

0

2.21

1

3Q
10

2Q
10

2.13

4

1Q
10

2.21

2

4Q
09

3Q
09

Survey Market Trend

W eig h ted Avg . P rice

V alu e M illion US $

P ack M illion

3

670
640
610
580
550
520
490
460
430
400
370
340
310
280
250
220
190
160
130
100
70
40

10


MAT

Import Vs. Local

2Q 14

Volume (mill UNIT)

Value (mill US$)
2,432

1,546

35%
+6%

31%
+3%

+4%
65%

+3%
69%

Total

7

Hospital

886

43%
+11%

+6%
57%

Pharmacy

Local

Imported

19,712

9,103

10,609

+6%
75%

+7%
77%

+5%
74%

+1%
25%

+1%
23%

+0%
26%

Total

Hospital

Pharmacy


MAT

Branded Vs. Generic

2Q 14

Volume (mill UNIT)

Value (mill US$)

8

2,432

1,546

886

+3%
74%

+1%
75%

+7%
72%

+10%
26%

+11%
25%

+9%
28%

Total

Hospital

Pharmacy

19,712

9,103

10,609

+5%
92%

+6%
94%

+3%
91%

+1%
8%

-8%
6%

+7%
9%

Hospital

Pharmacy

Generic

Branded

Total


Agenda slide

• Market Overview
• Survey Market Top Lines
• Leading Corporations
• Leading Products
• New Products

9


MAT

Leading Corporations

2Q 14

Survey Market:
US$ 2,432 mill (+5%)

Managed Products:
US$ 2,424 mill (+5%)
%

MAT SPLY QTR

Million US$

1

1

1

SANOFI

2

2

2

GSK

3

4

5

NOVARTIS

4

DHG PHARMA

3

ASTRAZENECA

4
5
6

3
5
9

6

ROCHE

7

7

8

MSD

8

6

7

PFIZER

9

8

9

SERVIER

10

16

12

±%

BOEH. INGEL.

80.3

0.00

46.2

0.06

44.7

0.19

37.3
32.9

3.5%

0%

96

0.42

567

-4%

10%

105

7.42

277

-8%

2.3%

8%

104

4.27

131

-1%

54.7

2.3%

-7%

89

-4.13

1,076

-1%

2.2%

14%

109

6.56

64

0%

2.1%

32%

126

12.22

18

14%

1.9%

9%

104

3.87

101

0%

1.8%

3%

98

1.24

90

16%

1.5%

-7%

89

-2.79

209

-12%

50.5

0.29

±%

3.3%

52.9

0.02

UNIT

55.1

0.13
0.35

V/Increase

(mill US$) (mill Unit) UNIT

84.9

1.12

EI

1.4%

20%

115

5.55

109

15%

31.2

1.3%

13%

108

3.62

59

-5%

30.8

1.3%

12%

107

3.38

393

18%

29.6

1.2%

-1%

94

-0.40

520

-12%

29.4

1.2%

-14%

82

-4.75

47

-13%

0.00

11

14

10

BAYER H/C

12

15

14

BIDIPHAR

13

12

17

TRAPHACO

14

10

11

FRESENIUS BIDIPHAR

15

19

16

DOMESCO

29.1

1.2%

20%

115

4.95

677

19%

29.0

1.2%

12%

107

3.14

73

15%

1.1%

0%

95

-0.11

450

-9%

1.0%

25%

120

5.10

4

1%

23.6

1.0%

18%

113

3.65

48

32%

23.4

1.0%

7%

103

1.59

1

16%

16

18

13

J&J

17

13

18

STADA

18

23

19

BAXTER

19

24

22

ST.PAUL BRANDS

20

21

15

HOSPIRA

0.05

0.00

0.03
0.00

0.00

27.9
25.2


OTC MAT
2Q 14

Leading Corporations
Survey Market:
US$ 803 mill (+9%)

Managed Products:
US$ 802 mill (+9%)
%

MAT SPLY QTR

Million US$

1

1

1

2

2

2

TRAPHACO

3

DHG PHARMA

23.7

4

ST.PAUL BRANDS

23.6
13.7
13.5

4

3
4

5

9

6

BOEH. INGEL.

6

6

5

IPSEN

7

5

10

8

18

9

9

7

14

V/Increase

UNIT

±%

3.9%

5%

97

1.54

297

-2%

3.6%

-1%

91

-0.23

503

-12%

3.0%

4%

96

0.93

718

0%

2.9%

18%

109

3.65

48

32%

1.7%

10%

102

1.28

79

12%

1.7%

-1%

91

-0.16

79

0%

1.6%

-6%

87

-0.85

201

-15%

12.4

1.6%

64%

151

4.84

104

73%

12.4

0.02

28.7

0.00

13.1

GSK 0.00
HOA THIEN PHU

EI

(mill US$) (mill Unit) UNIT

31.5

SANOFI

3

±%

1.6%

-5%

87

-0.67

228

0%

TU VAN YD Q/TE-IMC

11.9

1.5%

11%

102

1.18

44

7%

11.9

1.5%

5%

97

0.54

213

-20%

11.7

1.5%

-9%

84

-1.16

155

-11%

1.3%

10%

101

0.94

54

15%

10.0

1.2%

3%

95

0.29

73

-2%

9.6

1.2%

0%

92

-0.02

70

1%

1.1%

16%

107

1.27

33

26%

MEGA LIFESCIENCES

0.00

10

11

11

11

10

8

OPC (TW26)

12

8

7

UNITED PHARMA

13

15

13

14

13

15

MSD 0.00

15

14

12

BMS

16

17

16

NOVARTIS

17

20

17

NHAT NHAT

8.7

1.1%

23%

114

1.66

75

15%

18

12

18

NAM DUOC

8.7

1.1%

-16%

77

-1.69

74

-18%

19

16

19

PHARMEDIC

8.4

1.1%

3%

95

0.24

234

-14%

20

19

20

BIDIPHAR

8.3

1.0%

16%

107

1.12

257

23%

J&J

0.00
0.03

0.00
0.00

10.5

9.2


Ethical MAT
2Q 14

Leading Corporations
Survey Market:
US$ 1,629 mill (+3%)

Managed Products:
US$ 1,622 mill (+3%)
%

MAT SPLY QTR

1

1

1

2

2

4

SANOFI

3

3

2

ASTRAZENECA

4

6

3

ROCHE

5

5

6

NOVARTIS

4

5

EI

V/Increase

Million US$
GSK

6

±%

PFIZER

7

9

7

MSD

8

8

9

SERVIER

9

7

8

DHG PHARMA

53.3

1.1

52.3

0.02

49.5

0.29

45.9

0.35

44.7

0.1

36.2

0.06

32.5
30.9

±%

(mill US$) (mill Unit) UNIT

67.1

0.13

UNIT

4.1%

14%

111

8.27

76

17%

3.3%

-2%

95

-1.12

270

-6%

3.2%

14%

111

6.60

64

0%

3.1%

34%

130

12.48

16

18%

2.8%

7%

104

2.99

98

-7%

2.8%

3%

100

1.23

90

16%

2.2%

11%

108

3.57

28

5%

2.0%

-4%

93

-1.51

174

-10%

1.9%

-14%

84

-5.06

358

-2%

26.3

1.6%

-12%

85

-3.67

41

-13%

25.8

1.6%

19%

116

4.18

44

0%

10

10

10

FRESENIUS BIDIPHAR

11

14

12

BAYER H/C

12

15

14

DOMESCO

25.5

1.6%

23%

119

4.72

487

27%

13

18

13

BAXTER

25.2

1.6%

25%

122

5.10

4

1%

14

13

11

HOSPIRA

23.4

1.4%

7%

104

1.59

1

16%

15

12

15

STADA

23.0

1.4%

4%

101

0.96

338

-2%

16

17

17

BIDIPHAR

22.5

1.4%

11%

108

2.26

136

10%

17

16

16

MERCK SERONO

19.6

1.2%

-4%

94

-0.72

112

-3%

18

24

19

BOEH. INGEL.

19.2

1.2%

29%

125

4.27

30

25%

19

22

18

J&J

18.5

1.1%

14%

110

2.20

19

15%

20

11

22

18.2

1.1%

-32%

67

-8.40

132

-20%

PYMEPHARCO

>>

0
0.02

0
0

0
0


Pharmacy MAT
2Q 14

Leading Corporations
Managed Products:
US$ 883 mill (+8%)

Survey Market:
US$ 886 mill (+8%)

%

MAT SPLY QTR

Million US$

1

1

1

SANOFI

2

2

2

GSK

3

3

3

DHG PHARMA

4

4

4

NOVARTIS

5

5

7

6

6

MSD

7

9

5

PFIZER

8

8

8

BOEH. INGEL.

7

9

0.54

39.1

0.13

26.4

10

10

STADA

11

11

12

BAYER H/C

12

12

14

ASTRAZENECA

13

14

15

J&J

14

16

11

TRAPHACO

15

24

17

HOA THIEN PHU

16

13

20

MEGA LIFESCIENCES

17

17

19

TU VAN YD Q/TE-IMC

18

18

13

MERCK SERONO

19

15

16

UNITED PHARMA

20

20

18

IPSEN

0
0

99

3.48

446

5%

4.4%

3%

96

1.20

225

-10%

649

10%

2.6%

10%

102

2.15

88

-6%

22.8

2.6%

17%

109

3.36

47

31%

2.3%

9%

101

1.62

87

2%

20.0

2.3%

26%

117

4.11

59

38%

19.6

2.2%

14%

106

2.41

85

14%

19.2

2.2%

2%

95

0.42

115

-1%

1.7%

2%

95

0.34

248

-5%

13.8

1.6%

-7%

87

-0.98

41

-10%

13.3

1.5%

0%

92

-0.04

28

2%

13.2

20.6

15.4

0

0

7%

3.83

0

0

5.8%

108

0.18

0

±%

17%

0.06

0.02

UNIT

3.0%

0.1

0.02

V/Increase

23.0

SERVIER

10

EI

(mill US$) (mill Unit) UNIT

51.5

ST.PAUL BRANDS

6

9

±%

1.5%

7%

99

0.83

54

12%

12.5

1.4%

16%

108

1.76

257

4%

12.3

1.4%

64%

152

4.78

103

74%

12.2

1.4%

-2%

91

-0.26

208

0%

11.6

1.3%

12%

104

1.21

42

7%

11.3

1.3%

12%

104

1.18

92

17%

11.1

1.3%

-5%

88

-0.61

151

-9%

10.1

1.1%

9%

101

0.82

59

11%


Hospital MAT
2Q 14

Leading Corporations
Managed Products:
US$ 1,541 mill (+3%)

Survey Market:
US$ 1,546 mill (+3%)

%

MAT SPLY QTR

1

5

2

2

3

3

GSK

1

ASTRAZENECA

4

SANOFI

4

4
1

5

7

5

NOVARTIS

6

10

10

BIDIPHAR

7

2

9

DHG PHARMA

8

6

7

FRESENIUS BIDIPHAR

9

11

11

10

8

6

EI

V/Increase

Million US$
ROCHE

3

±%

MSD
PFIZER

11

14

12

12

12

8

HOSPIRA

13

19

13

DOMESCO

41.1

0

39.7

0

33.3

0.58

32.1

0
0
0

BAXTER

20.4

32%

129

10.64

8

18%

2.7%

18%

115

6.22

52

-2%

2.6%

20%

117

6.61

36

-1%

2.2%

-8%

89

-3.06

121

-27%

2.1%

7%

104

2.11

43

11%

1.9%

12%

109

3.12

336

21%

28.3

1.8%

-22%

76

-7.95

427

-14%

25.8

1.7%

-18%

80

-5.49

39

-17%

25.6

1.7%

10%

107

2.25

14

-13%

24.7

1.6%

-10%

87

-2.86

31

-11%

24.3

1.6%

24%

120

4.64

4

2%

1.5%

7%

104

1.57

0.5

16%

23.3

0

2.8%

28.8

0.25

0

±%

(mill US$) (mill Unit) UNIT

43.7

0

UNIT

1.3%

26%

123

4.25

346

34%

>>

18.3

1.2%

-32%

66

-8.70

172

-11%

18.1

1.2%

-15%

83

-3.21

93

-23%

17.4

1.1%

36%

132

4.60

17

9%

17.1

1.1%

-11%

86

-2.16

262

-24%

14

9

16

15

13

15

SERVIER

16

24

14

BAYER H/C

17

16

24

TRAPHACO

18

17

19

B.BRAUN

16.6

1.1%

-8%

90

-1.37

14

-16%

19

21

18

PHARBACO (TW1)

16.5

1.1%

16%

113

2.31

112

-35%

20

22

17

J&J

15.8

1.0%

17%

114

2.31

19

25%

PYMEPHARCO

0.03

0.03

MAT

OTC Vs. Ethical

2Q 14
% Growth by UNIT

% Growth by US$
Rank
1
2

Corporation

OTC

67%

9%

3%

5%

-2%

33%
37%

SANOFI

GSK

% Share by US$

63%

Ethical

16%

84%

-6%

14%

17%

83%

16%

7%

4%

-14%

61%

4

DHG PHARMA

5

ASTRAZENECA

1%

99%

-5%

14%

6

ROCHE

2%

98%

-20%

34%

7

MSD

3%

11%

8

PFIZER

340%

3%

OTC
0%

9

SERVIER

-21%

-4%

Rx

10%

29%

-10%

19%

16%

11%

-1%

-16%

-27%

-12%

7%

23%

10%

14%

-18%

4%

-20%

25%

18%

0%

0%

7%

22%

78%

0%

100%

13%

87%

10

BOEH. INGEL.

11

BAYER H/C

12

BIDIPHAR

13

TRAPHACO

14

10%
FRESENIUS BIDIPHAR

15

DOMESCO

16

J&J

17

STADA

17%

18

BAXTER

0%

19

ST.PAUL BRANDS

20

HOSPIRA

42%
17%

83%
73%

27%
97%

3%

90%

13%

87%
64%

36%

83%
100%
100%

0%

100%

0%

48%

73%

NOVARTIS

57%

39%

52%

3

43%

OTC

% Share by UNIT

27%

25%

75%
67%

0%

33%
100%

10%

90%
73%

27%
100%

17%

83%
72%

28%

26%

74%
35%

65%
97%
13%

3%

87%

28%

72%
74%

26%

25%
0%

75%
100%
100%

0%

100%

0%

Ethical
5%

5%

-2%

-6%

-15%

17%

26%

-7%

0%

-2%

-6%

0%

-14%

18%

-2%

5%

20%

16%

-21%

-10%

12%

25%

-16%

0%

23%

10%

-12%

-23%

-17%

-13%

2%

27%

15%

15%

-26%

-2%

-14%

1%

32%

0%

0%

16%


MAT

Pharmacy Vs. Hospital

2Q 14
% Growth by UNIT

% Growth by US$
Rank

Pharmacy

% Share by US$

Corporation

36%

64%

Hospital

7%

-8%

79%

3%

18%

81%

10%

7%

17%

-22%

0%

20%

30%

32%

2

GSK

3

NOVARTIS

4

DHG PHARMA

5

ASTRAZENECA

6

ROCHE

7

MSD

45%

55%

9%

10%

8

PFIZER

45%

55%

26%

-10%

9

SERVIER

2%

-15%

14%

31%

-7%

36%

15%

12%

16%

-11%

27%

-18%

9%

26%

7%

17%

2%

-3%

108%

24%

17%

59%

0%

7%

49%

51%

42%

58%

48%

52%

25%

75%

14%

86%

51%

10

BOEH. INGEL.

11

BAYER H/C

12

BIDIPHAR

13

TRAPHACO

14

FRESENIUS BIDIPHAR

15

DOMESCO

16

J&J

17

STADA

18

BAXTER

19

ST.PAUL BRANDS

20

HOSPIRA

49%

60%

40%

44%

56%
93%

7%
42%
12%

58%
88%

30%

70%

46%

54%

55%
4%

45%

96%
97%

0%

100%

3%

Pharmacy
46%

3%

SANOFI

39%

54%

8%

1

61%

% Share by UNIT

67%

4%

21%

5%

-27%

19%

-10%

-2%

-6%

11%

10%

-14%

2%

-1%

11%

18%

2%

-13%

38%

-11%

-1%

-23%

14%

19%

-10%

9%

4%

21%

4%

-24%

12%

-17%

7%

34%

12%

25%

-5%

-14%

-34%

2%

3%31%

66%

0%

16%

40%

44%

56%

55%

45%
87%

Pharmacy

13%

65%

Hospital

35%

55%

45%
78%

22%

71%

29%
85%

15%

50%

50%

18%

82%
49%

51%
74%

26%

55%
2%

45%
98%
97%

0%

6%

33%

60%

100%

Hospital


MAT

Growth Comparison

2Q 14
Managed Products:
US$ 2,424 mill (+5%)

Rank

Corporation

1

SANOFI

2

GSK

3

NOVARTIS

4

DHG PHARMA

5

ASTRAZENECA

6

ROCHE

7

MSD

8

PFIZER

9

SERVIER

10

BOEH. INGEL.

11

BAYER H/C

12

BIDIPHAR

13

TRAPHACO

14

FRESENIUS BIDIPHAR

15

DOMESCO

16

J&J

17

STADA

18

BAXTER

19

ST.PAUL BRANDS

20

HOSPIRA

84.85

0.5%

80.25

10.2%

55.12

8.4%

54.68

-7.0%

52.94

14.2%

50.51

31.9%

46.18

9.1%

44.69

2.9%

37.34

-7.0%

32.89

20.3%

31.20

13.1%

30.80

12.3%

29.58

-1.3%

29.35

-13.9%

29.14

20.5%

28.98

12.2%

27.86

-0.4%

25.17

25.4%

23.59

18.3%

23.36

7.3%

-20%

-10%

0%

10%

20%

30%

40%


Agenda slide

• Market Overview
• Survey Market Top Lines
• Leading Corporations
• Leading Products
• New Products

18


Top 10 Fastest Growing Therapy Classes Level III
Cut-off size: US$ 500,000
Rank

±%

000 US$ Corporation Leading

1

OTHER IMAGING AGENTS - T01X

2

DPP-IV INHIBITOR A-DIABS - A10N

3

VITAMIN K ANTAGONISTS - B01A

4

SPEC ANTIRHEUMATIC AGENT - M01C

5

LIP.REG.CO.W.OTH.LIP.REG - C10C

6

BLOOD COAGULATION - B02D

72%

5,797

7

PROTEIN KINASE INH A-NEO - L01H

70%

22,246

8

IRON-CHELATING AGENTS - V03F

9

ANTI-TNF PRODUCTS - L04B

113%
105%
94%
81%
76%

65%
56%

524

GUERBET

Share in
TC3s

Product Leading

100.0%

LIPIODOL - GUERBET

Share in TC3s
100.0%

46.0%

JANUVIA - MSD

26.3%

77.8%

COUMADINE

>>
42.4%

ROCHE

97.3%

ACTEMRA - ROCHE

FORIPHARM (TW3)

38.3%

LUMBROTINE - FORIPHARM (TW3) 38.3%

BAXTER

36.6%

HEMOFIL M - BAXTER

36.6%

ROCHE

38.3%

TARCEVA - ROCHE

38.3%

NOVARTIS

66.5%

DESFERAL - NOVARTIS

36.1%

J&J

60.6%

REMICADE - J&J

60.6%

3,877

SOPHARMA

67.8%

NIVALIN - SOPHARMA

93.9%

1,303

SINENSIX

30.4%

IMUTAC - SINENSIX

30.4%

FRESENIUS BIDIPHAR

29.5%

KABIVEN PERIPHERAL - FRESENIUS11.0%
BIDIPHAR

2,573

MSD

818

ECO

685
724

3,116
901

>>

E10>> - ECO

97.3%

10

ANTI-ALZHEIMER PRODUCTS - N07D

11

OTH N-STER INFLAM SKIN - D05X

12

FAT EMULSIONS,INCL TPN - K01D

43%

13,195

13

HAEMO DIALYSIS SOLUTIONS - K06A

42%

3,821

B.BRAUN

69.0%

HD-1B LIQ CONC - B.BRAUN

14

OTHER METABOLIC PRODUCTS - A16A

42%

5,648

FRESENIUS BIDIPHAR

46.7%

KETOSTERIL - FRESENIUS BIDIPHAR
46.7%

15

PROTEIN SUPPLEMENTS - V06B

41%

3,121

PT SOHO INDUSTRI

21.9%

AMINORAL - PT SOHO INDUSTRI 21.9%

16

TOP ANTIPSORIASIS PRDS - D05A

36%

1,399

LEO

81.7%

DAIVOBET - LEO

31.8%

17

ANGIOTEN-II ANTAG, COMB - C09D

36%

12,675

PSYCHOTROPICS

25.3%

TELPIL H - PSYCHOTROPICS

25.3%

18

ANTICHOLINERGIC+B2-STIMUL - R03G

35%

5,179

BERODUAL - BOEH. INGEL.

51.4%

19

OTHER DERMATOLOGICALS - D11A

33%

36,171

HOA THIEN PHU

24.1%

SAC NGOC KHANG - HOA THIEN PHU
21.2%

20

MAB ANTINEOPLASTICS - L01G

33%

18,816

ROCHE

74.4%

MABTHERA - ROCHE

52%
49%

BOEH. INGEL.

100.0%

41.3%

30.8%


Leading Therapy Classes Level III

Rank

Corporation Leading

Million US$

1

CEPHALOSPORINS & COMBS - J01D

2

ANTIULCERANTS - A02B

3

BROAD SPECTRUM PENICILLIN - J01C

4

NON-NARCOTIC ANALGESICS - N02B

5

221.9

GSK

Share in
TC3s
7.8%

Product Leading

Share in TC3s

ZINNAT - GSK

5.9%

ASTRAZENECA

13.4%

NEXIUM - ASTRAZENECA

11.8%

GSK

26.8%

AUGMENTIN - GSK

24.7%

56.1

BMS

17.9%

EFFERALGAN - BMS

10.9%

OTH MUSCULO-SKELETAL PRDS - M05X

56.0

ST.PAUL BRANDS

14.9%

JEX - ST.PAUL BRANDS

14.8%

6

CEREB.+PERIPHE.VASOTHERAP - C04A

51.9

TRAPHACO

14.6%

HOAT HUYET D/NAO - TRAPHACO 10.8%

7

HEPAT PROTECT-LIPOTROPICS - A05B

51.8

TRAPHACO

12.0%

BOGANIC - TRAPHACO

11.8%

8

OTH B-LACTAM EX PEN,CEPH - J01P

MSD

28.3%

TIENAM - MSD

23.5%

9

ALL OTH.THERAPEUTIC PRDS - V03X

42.1

JSC SCIENTIFIC

10

FLUOROQUINOLONES - J01G

39.0

BAYER H/C

21.0%

CIPROBAY - BAYER H/C

15.4%

11

ANTIRHEUMATIC NON-STEROID - M01A

37.8

BOEH. INGEL.

12.8%

MOBIC - BOEH. INGEL.

12.8%

12

OTHER DERMATOLOGICALS - D11A

36.2

HOA THIEN PHU

24.1%

SAC NGOC KHANG - HOA THIEN PHU
21.2%

13

CHOLEST&TRIGLY.REGULATOR - C10A

34.9

ASTRAZENECA

13.3%

CRESTOR - ASTRAZENECA

13.3%

14

CALCIUM - A12A

34.5

SANOFI

23.4%

CALCIUM CORBIERE - SANOFI

23.3%

15

VINCA ALKALOIDS - L01C

33.2

HOSPIRA

34.6%

ANZATAX - HOSPIRA

22.8%

16

MACROLIDES & SIMILAR TYPE - J01F

31.1

PFIZER

14.6%

ZITHROMAX - PFIZER

10.4%

17

PROTEIN SOLUTIONS - K03B

29.5

BAXTER

26.3%

HUMAN ALBUMIN - BAXTER

26.3%

18

TONICS - A13A

29.4

ST.PAUL BRANDS

16.7%

ALIPAS - ST.PAUL BRANDS

16.7%

19

ANTI-INFLAMMATORY ENZYME - V03H

27.8

SANOFI

29.4%

ALPHACHYMOTRYPSIN - SANOFI 29.4%

20

NOOTROPICS - N06D

25.4

ITALFARMACO

22.3%

GLIATILIN - ITALFARMACO

78.9
71.0

46.7

5.8%

REAMBERIN - JSC SCIENTIFIC

5.8%

22.3%


MAT

Leading Products
Survey Market:
US$ 2,432 mill (+5%)

2Q 14
Managed Products:
US$ 2,424 mill (+5%)
%

MAT SPLY QTR

±%

EI

V/Increase

Million US$

1

1

2

AUGMENTIN - GSK

2

2

3

ZINNAT - GSK

3

3

1

MERONEM - ASTRAZENECA

10.97

TIENAM - MSD

10.97

4

4

5

5

5

6

DIANEAL LOW CALCI - BAXTER

6

6

8

DIAMICRON - SERVIER

7

7

9

NEXIUM - ASTRAZENECA

8

8

7

CEREBROLYSIN - EVER NEURO PHARMA

9

9

13

10

10

16

11

11

12

10.54
9.60
9.28
8.90

±%

(mill US$) (mill Unit) UNIT

17.55
13.17

UNIT

0.72%

19%

114

2.78

25.77

17%

0.54%

18%

113

2.05

15.98

22%

0.45%

23%

118

2.08

0.33

19%

0.45%

7%

102

0.74

0.68

5%

0.43%

0%

96

0.00

2.99

0%

0.39%

-6%

90

-0.62

64.40

-11%

0.38%

17%

112

1.37

5.91

13%

0.37%

13%

108

1.04

1.98

15%

0.35%

62%

155

3.27

0.15

72%

MIXTARD 30 - NOVO NORDISK A/S

8.32

0.34%

19%

114

1.33

1.05

32%

19

JEX - ST.PAUL BRANDS

8.30

0.34%

73%

165

3.50

19.35

75%

12

14

COVERSYL - SERVIER

8.28

0.34%

0%

95

-0.02

32.61

0%

13

13

28

ALPHACHYMOTRYPSIN - SANOFI

8.19

0.34%

24%

119

1.61

107.75

26%

14

14

11

CALCIUM CORBIERE - SANOFI

8.06

0.33%

2%

97

0.15

44.60

-1%

15

15

23

HUMAN ALBUMIN - BAXTER

7.76

0.32%

62%

155

2.98

0.19

64%

16

16

15

SAC NGOC KHANG - HOA THIEN PHU

7.67

0.32% 129%

218

4.32

62.39

134%

17

17

12

PLAVIX - SANOFI

7.62

0.31%

12%

107

0.83

7.75

15%

18

18

4

ANZATAX - HOSPIRA

7.57

0.31%

5%

101

0.39

0.05

16%

19

19

27

HAGINAT - DHG PHARMA

6.55

0.27%

-14%

82

-1.09

15.74

-4%

20

20

34

BISEKO - BIOTEST PHARMA

6.33

0.26%

49%

143

2.09

0.15

52%

8.53

TARCEVA - ROCHE


Leading Products
Survey Market:
US$ 803 mill (+9%)

2
3

1
2
3

3

1
2

MAT

2Q 14

Managed Products:
US$ 802 mill (+9%)
%

MAT SPLY QTR

1

OTC

±%

EI

Million US$

8.06

CALCIUM CORBIERE - SANOFI

7.67

SAC NGOC KHANG - HOA THIEN PHU

UNIT

±%

(mill US$) (mill Unit) UNIT

8.30

JEX - ST.PAUL BRANDS

V/Increase

1.03%

73%

160

3.50

19.3

75%

1.00%

2%

94

0.15

44.6

-1%

0.96% 129%

211

4.32

62.4

134%

0.76%

12%

103

0.64

50.5

13%

4

4

4

EFFERALGAN - BMS

6.12

5

5

8

BOGANIC - TRAPHACO

6.09

0.76%

-21%

72

-1.66

139.4

-21%

6

6

6

TANAKAN - IPSEN

6.01

7
8
9

7
8
9

12
5
7

0.75%

-2%

90

-0.12

32.3

-2%

HOAT HUYET NHATNHA - NHAT NHAT

5.83

0.73%

4%

96

0.23

54.1

-4%

ENTEROGERMINA - SANOFI

5.70

0.71%

34%

123

1.44

20.8

34%

5.58

0.69%

13%

104

0.64

183.9

2%

0.65%

-27%

68

-1.90

11.7

-25%

HOAT HUYET D/NAO - TRAPHACO

5.20

10

10

11

ANGELA WOMENS GINS - ST.PAUL BRANDS

11

11

14

ALIPAS - ST.PAUL BRANDS

4.91

0.61%

-33%

62

-2.43

5.6

-32%

12

12

10

MARVELON - MSD

4.84

0.60%

26%

116

0.99

40.6

29%

13

13

9

HAPACOL - DHG PHARMA

4.79

14

14

16

0.60%

26%

116

0.99

121.9

6%

PHARMATON - BOEH. INGEL.

4.53

0.56%

6%

98

0.25

22.2

6%

0.56%

-21%

72

-1.23

32.0

-21%

0.55%

-10%

83

-0.48

102.8

-15%

0.53%

78%

164

1.87

1.5

74%

0.49%

3%

95

0.12

82.6

6%

15

15

13

DAFLON - SERVIER

4.50

16

16

29

PANADOL EXTRA - GSK

4.44

17

17

15

PROSPAN - ENGELHARD ARZNEIMI

18

18

17

SALONPAS - HISAMITSU

19

19

27

STREPSILS - RECKITT BENCKISER

3.57

0.44%

1%

93

0.02

66.0

-3%

20

20

18

PHOSPHALUGEL - BOEH. INGEL.

3.52

0.44%

7%

99

0.23

21.5

8%

4.29
3.97


Ethical MAT
2Q 14

Leading Products
Survey Market:

US$ 1,629 mill (+3%)

Managed Products:
US$ 1,622 mill (+3%)
%

MAT SPLY QTR

115

2.78

25.77

17%

0.81%

18%

115

2.05

15.98

22%

0.67%

23%

120

2.08

0.33

19%

0.67%

7%

104

0.74

0.68

5%

0.65%

0%

97

0.00

2.99

0%

0.59%

-6%

91

-0.62

64.40

-11%

0.57%

17%

114

1.37

5.91

13%

0.55%

13%

110

1.04

1.98

15%

8.53

0.52%

62%

158

3.27

0.15

72%

0.51%

19%

116

1.33

1.05

32%

-0.02

32.61

0%

2

2

3

ZINNAT - GSK

3

3

1

MERONEM - ASTRAZENECA

10.97

TIENAM - MSD

10.97

5

6

DIANEAL LOW CALCI - BAXTER

6

6

8

DIAMICRON - SERVIER

7

7

9

NEXIUM - ASTRAZENECA

8

8

7

CEREBROLYSIN - EVER NEURO PHARMA

9

9

12

13.17

10.54
9.60
9.28
8.90

TARCEVA - ROCHE

±%

19%

AUGMENTIN - GSK

5

UNIT

1.08%

2

5

V/Increase

(mill US$) (mill Unit) UNIT

17.55

1

4

EI

Million US$

1

4

±%

10

10

14

MIXTARD 30 - NOVO NORDISK A/S

8.32

11

11

13

COVERSYL - SERVIER

8.28

0.51%

0%

97

12

12

23

ALPHACHYMOTRYPSIN - SANOFI

8.19

0.50%

24%

121

1.61 107.75

26%

13

13

19

HUMAN ALBUMIN - BAXTER

7.76

0.48%

62%

158

2.98

0.19

64%

14

14

11

PLAVIX - SANOFI

7.62

0.47%

12%

109

0.83

7.75

15%

15

15

4

ANZATAX - HOSPIRA

7.57

0.46%

5%

102

0.39

0.05

16%

16

16

22

HAGINAT - DHG PHARMA

6.55

0.40%

-14%

83

-1.09

15.74

-4%

17

17

27

BISEKO - BIOTEST PHARMA

6.33

0.39%

49%

145

2.09

0.15

52%

18

18

28

CONCOR - MERCK SERONO

6.26

0.38%

5%

102

0.28

40.11

6%

19

19

21

DBL OXALIPLATIN - HOSPIRA

6.25

0.38%

5%

102

0.32

0.05

55%

20

20

15

CIPROBAY - BAYER H/C

6.01

0.37%

46%

142

1.90

3.64

26%


Leading Products

Pharmacy

MAT

2Q 14

Managed Products:
US$ 883 mill (+8%)

Survey Market:
US$ 886 mill (+8%)

%

MAT SPLY QTR

±%

EI

V/Increase

Million US$

1

1

4

AUGMENTIN - GSK

2

2

5

JEX - ST.PAUL BRANDS

3

3

1

SAC NGOC KHANG - HOA THIEN PHU

4

4

2

ZINNAT - GSK

5

5

3

CALCIUM CORBIERE - SANOFI

6

6

8

ALPHACHYMOTRYPSIN - SANOFI

7

7

15

8

8

6

9

9

14

10

10

7

11

11

12

1.16%

9%

102

0.89

16.3

13%

0.90%

73%

161

3.37

18.6

75%

0.86% 129%

213

4.29

61.8

135%

7.18

0.81%

12%

104

0.75

9.0

16%

7.18

0.81%

10%

102

0.67

39.4

7%

0.74%

42%

132

1.94

85.7

44%

0.60%

1%

94

0.06

49.8

-6%

7.98
7.61

6.54
5.35

±%

(mill US$) (mill Unit) UNIT

10.32

HOAT HUYET NHATNHA - NHAT NHAT

UNIT

EFFERALGAN - BMS

5.16

0.58%

17%

108

0.73

42.4

18%

ANGELA WOMENS GINS - ST.PAUL BRANDS

5.03

0.57%

-28%

67

-1.93

11.4

-26%

TANAKAN - IPSEN

4.83

0.54%

7%

99

0.31

26.0

9%

16

ALIPAS - ST.PAUL BRANDS

4.74

0.54%

-34%

61

-2.45

5.4

-33%

12

13

DIAMICRON - SERVIER

4.72

0.53%

-2%

91

-0.11

32.7

-9%

13

13

10

MARVELON - MSD

4.65

0.53%

25%

116

0.94

39.1

28%

14

14

17

PHARMATON - BOEH. INGEL.

4.45

0.50%

6%

98

0.24

21.8

6%

15

15

9

ENTEROGERMINA - SANOFI

4.37

0.49%

28%

119

0.95

16.0

28%

16

16

35

PANADOL EXTRA - GSK

4.23

0.48%

-10%

84

-0.45

98.1

-15%

17

17

12

GLUCOPHAGE - MERCK SERONO

0.45%

20%

112

0.68

33.4

22%

18

18

11

HOAT HUYET D/NAO - TRAPHACO

3.73

0.42%

36%

127

1.00

120.1

17%

19

19

20

SALONPAS - HISAMITSU

3.69

0.42%

2%

94

0.06

76.4

4%

20

20

18

CEREBROLYSIN - EVER NEURO PHARMA

3.63

0.41%

16%

108

0.50

0.8

19%

4.00


Leading Products
Survey Market:
US$ 1,546 mill (+3%)

Hospital

%

±%

EI

Million US$

1

1

MERONEM - ASTRAZENECA

2

2

3

TIENAM - MSD

3

3

4

DIANEAL LOW CALCI - BAXTER

4

4

7

TARCEVA - ROCHE

5

5

2

ANZATAX - HOSPIRA

6

6

6

AUGMENTIN - GSK

7

7

18

HUMAN ALBUMIN - BAXTER

8

8

14

NEXIUM - ASTRAZENECA

9

9

20

MIXTARD 30 - NOVO NORDISK A/S

10

10

16

BISEKO - BIOTEST PHARMA

11

11

10

DBL OXALIPLATIN - HOSPIRA

12

12

15

ZINNAT - GSK

13

13

13

MABTHERA - ROCHE

14

14

5

HUMAN ALBUMIN - HUMAN BIOPLAZMA

15

15

26

SEVORANE - ABBVIE

16

16

24

HAGINAT - DHG PHARMA

17

17

9

18

18

19

19

20

20 103

2Q 14

Managed Products:
US$ 1,541 mill (+3%)

MAT SPLY QTR

1

MAT

V/Increase

UNIT

±%

(mill US$) (mill Unit) UNIT

0.70%

24%

121

2.11

0.33

19%

0.70%

8%

105

0.77

0.67

5%

0.68%

0%

97

0.00

2.99

0%

0.54%

62%

157

3.18

0.15

72%

0.49%

5%

102

0.39

0.05

16%

7.24

0.47%

35%

131

1.89

9.42

26%

7.14

0.46%

53%

149

2.49

0.17

54%

0.44%

24%

120

1.30

3.35

18%

0.43%

21%

118

1.16

0.87

35%

6.29

0.41%

50%

145

2.09

0.15

52%

6.24

0.40%

5%

102

0.31

0.05

55%

0.39%

28%

124

1.30

7.02

31%

5.79

0.37%

-1%

96

-0.06

0.00

2%

5.74

0.37%

20%

116

0.95

0.12

41%

0.36%

31%

127

1.30

0.03

18%

5.32

0.34%

-16%

82

-0.99

12.53

-3%

GLIATILIN - ITALFARMACO

5.30

0.34%

2%

99

0.08

1.50

0%

29

NANOKINE - NANOGEN PHARMA

5.27

0.34% 189%

280

3.44

0.48 233.8%

11

CEREBROLYSIN - EVER NEURO PHARMA

5.27

0.34%

11%

108

0.54

1.15

11%

INFANRIX HEXA - GSK

5.25

0.34%

31%

127

1.24

0.18

35%

10.88
10.82
10.54
8.31
7.57

6.77
6.59

5.99

5.49